Egros Fabrice
CIK: 0001597085
Associated companies
Transaction History
| SNDX | ▲ Buy | Grant | 16,000 | $0 | 2/2/2022 | View on chart |
| SNDX | ▲ Buy | Option Exercise | 14,000 | $125K | 11/18/2021 | View on chart |
| SNDX | ▼ Sell | Open Market | 14,000 | $252K | 11/18/2021 | View on chart |
| SNDX | ▲ Buy | Option Exercise | 30 | $236 | 11/18/2021 | View on chart |
| SNDX | ▼ Sell | Open Market | 30 | $541 | 11/18/2021 | View on chart |
| SNDX | ▲ Buy | Option Exercise | 15,635 | $123K | 8/18/2021 | View on chart |
| SNDX | ▼ Sell | Open Market | 15,635 | $246K | 8/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
SNDX Drops After Axatilimab IPF Trial Misses Endpoint
Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.
SNDX Drops After Axatilimab IPF Trial Misses Endpoint. Syndax Pharmaceuticals stock fell sharply after topline results from the MAXPIRe Phase 2 trial showed axatilimab did not meet its primary endpoint in idiopathic pulmonary fibrosis. The negative data triggered a significant selloff, with the stock dropping as much as 16% in after-hours trading. While some analysts maintain price targets, the trial outcome has raised questions about the drug's potential in this indication.